After Wedbush and RBC Capital gave Aimmune Therapeutics (NASDAQ: AIMT) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Charles Duncan maintained a Buy rating on Aimmune Therapeutics today and set a price target of $64.00. The company’s shares closed last Monday at $32.25.
According to TipRanks.com, Duncan is a 5-star analyst with an average return of 12.5% and a 53.5% success rate. Duncan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Inovio Pharmaceuticals.
Currently, the analyst consensus on Aimmune Therapeutics is a Moderate Buy with an average price target of $50.33, implying a 38.7% upside from current levels. In a report issued on January 21, Wedbush also reiterated a Buy rating on the stock with a $79.00 price target.
Based on Aimmune Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $64.46 million. In comparison, last year the company had a GAAP net loss of $57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.